@article{def748af1da14ba496c52b18498e79d5,
title = "Optimized Acute Treatment of Migraine Is Associated with Greater Productivity in People with Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study",
abstract = "Objective This study aimed to ascertain whether level of optimization of acute treatment of migraine is related to work productivity across the spectrum of migraine. Methods Data were from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study, an internet-based longitudinal survey. Respondents with migraine who reported full-time employment and use of ≥1 acute prescription medication for migraine were included. We determined relationships among lost productive time (LPT; measured with the Migraine Disability Assessment Scale), acute treatment optimization (Migraine Treatment Optimization Questionnaire-), and monthly headache days (MHDs). Results There was a direct relationship between LPT and MHD category. Greater acute treatment optimization was associated with lower total LPT, less absenteeism, and less presenteeism within each MHD category. Conclusions Optimizing acute treatment for migraine may reduce LPT in people with migraine and reduce indirect costs.",
keywords = "absenteeism, disability, employment, headache, migraine, presenteeism, productivity",
author = "Buse, {Dawn C.} and Nahas, {Stephanie J.} and Stewart, {Walter F.} and Armand, {Cynthia E.} and Reed, {Michael L.} and Fanning, {Kristina M.} and {Manack Adams}, Aubrey and Lipton, {Richard B.}",
note = "Funding Information: W.F.S. has served as a consultant to Amgen, Grifols, and Promius/Dr. Reddy's. C.E.A. has served as an advisory board member and has received honoraria from Biohaven and Impel Regional and from AbbVie and Teva. She is web editor of JAMA Neurology. M.L.R. is managing director of Vedanta Research, which has received research funding from AbbVie, Allay Lamp, Dr. Reddy's Laboratories, Eli Lilly, GlaxoSmithKline, and Promius via grants to the National Headache Foundation. Vedanta Research has received funding directly from AbbVie for work on the CaMEO and CaMEO-I Studies. K.M.F. is managing director of MIST Research, which, in collaboration with Vedanta Research, has received research funding from AbbVie, Allay Lamp, Dr. Reddy's Laboratories, Eli Lilly, GlaxoSmithKline, and NYU Langone Health via grants to the National Headache Foundation. MIST Research has received funding directly from AbbVie for work on the CaMEO and CaMEO-I Studies. A.M.A. is an employee of AbbVie and may hold AbbVie stock. R.B.L. is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the National Institutes of Health: 2PO1 AG003949 (mPI), 1RF1 AG057531 (site PI), RF1 AG054548 (investigator), 1RO1 AG048642 (investigator), R56 AG057548 (investigator), RO1 AG060933 (investigator), RO1 AG062622 (investigator), 1UG3FD006795 (mPI), 1U24NS113847 (investigator), U01 AT011005 (investigator), 1R01 AG075758 (pending — investigator), 1R01 AG077639 (pending — investigator), and K23 NS107643 (mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation and research grants from TEVA, Satsuma, and Amgen. He serves on the editorial board of Neurology and as senior advisor to Headache and associate editor to Cephalalgia. He has reviewed for the NIA and NINDS and holds stock and stock options in Biohaven Holdings and stock options in Manistee; serves as consultant or advisory board member, or has received honoraria from AbbVie (Allergan), American Academy of Neurology, American Headache Society, Amgen, Avanir, Axsome, Biohaven, Biovision, Boston Scientific, Dr. Reddy's (Promius), Electrocore, Eli Lilly, eNeura Therapeutics, Equinox, GlaxoSmithKline, Grifols, Lundbeck (Alder), Merck, Pernix, Pfizer, Satsuma, Supernus, Teva, Trigemina, Vector, and Vedanta. He receives royalties from Wolff's Headache 7th and 8th Edition, Oxford Press University, 2009, Wiley and Informa. Funding Information: Medical writing support was provided by Cory Hussar, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, and was funded by AbbVie. Funding Information: Conflict of interest: D.C.B. has received research support from the US Food and Drug Administration and the National Headache Foundation. She serves as consultant or advisory board member, or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Colleguium, Eli Lilly and Company, Lundbeck, and Teva and for work on the editorial board of Current Pain and Headache Reports in the past year. S.J.N. has received honoraria for consulting from Alder/Lundbeck, Allergan/AbbVie, Amgen/Novartis (ended April 2021), Axsome (ended January 2022), BioDelivery Sciences (ended February 2022), Biohaven (ended November 2021), Eli Lilly, Fenix Group International (ended July 2021), Teva (ended October 2021), and Theranica (ended September 2022). She has received honoraria for speaking from Allergan/AbbVie (ended July 2021), Amgen/Novartis (ended June 2021), Eli Lilly (ended September 2021), and Teva (ended June 2021); research support from Teva (Ended March 2021); and honoraria for work in education or publishing from American Academy of Neurology, American Headache Society, Evolve Med Ed, Massachusetts Medical Society, MedLink Neurology, MJH Life Sciences, NACCME, Neurology Learning Network, Pennsylvania Neurologic Society, Springer, WebMD/Medscape, and Wolters-Kluwer. Furthermore, she has received legal fees for serving as a medical expert to Jackson & Campbell. Publisher Copyright: {\textcopyright} Wolters Kluwer Health, Inc. All rights reserved.",
year = "2023",
month = apr,
day = "1",
doi = "10.1097/JOM.0000000000002801",
language = "English (US)",
volume = "65",
pages = "E261--E268",
journal = "Journal of Occupational and Environmental Medicine",
issn = "1076-2752",
publisher = "Lippincott Williams and Wilkins",
number = "4",
}
